Ajanta Pharma Limited

I'll research this company to build an accurate profile.

Let me verify the litigation context and US operations.

Company overview. Ajanta Pharma Limited (NSE: AJANTPHARM; BSE: 532331) is a publicly listed Indian specialty pharmaceutical manufacturer headquartered in Mumbai (Ajanta Tower, Andheri East). It was founded in 1973 by the Agrawal family (some sources cite a 1979 incorporation date), remains promoter-controlled, and has traded on Indian exchanges since 2000. Reported headcount is roughly 9,300–10,400 employees; FY2026 revenue was about ₹54.5 billion (~US$610 million), with market capitalization around ₹440 billion (~US$4.5 billion). (Sources: stockanalysis.com, FT, GlobalData, PitchBook.)

Products / operations. Ajanta develops, manufactures, and markets finished pharmaceutical dosages — tablets, capsules, eye drops, injectables, inhalers, creams, and liquids. It sells branded generics in India and emerging markets (Africa, Southeast Asia, West Asia, CIS) across cardiology, dermatology, ophthalmology, pain management, and more recently nephrology and gynaecology; its US business is generic, run through wholly owned subsidiary Ajanta Pharma USA Inc. (Bridgewater, New Jersey). Emerging-market lines include antimalarials, gastro, and antibiotics. It operates six formulation plants in India plus an API facility at Waluj; the Paithan (Maharashtra) and Dahej (Gujarat) sites are US FDA-approved. Roughly 49 ANDAs are commercialized in the US with about 19 pending.

Patent-litigation posture. Ajanta is an operating company, not an NPE. In the tracked data it appears once, solely as a defendant (0 plaintiff cases). That profile — generic manufacturer sued by a brand owner — is typical of Hatch-Waxman ANDA litigation. The venue is the District of Delaware, not an NPE-favored forum such as the Eastern District of Texas.

Notable case / context. The tracked suit, Merck Sharp & Dohme Corp. v. Ajanta Pharma Limited et al. (C.A. 1:20-cv-01496-RGA, D. Del., filed November 2020), was an ANDA/Paragraph IV action asserting U.S. Patent 7,326,708 concerning a Merck diabetes product; it ended in a consent judgment in September 2021. Public dockets show Ajanta is a repeat ANDA defendant in Delaware (e.g., suits by Pfizer, Supernus, Salix/Alfasigma, Boehringer Ingelheim), consistent with its US generics expansion, though those matters are not in our structured case list.